Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Faricimab in Patients With Choroidal Neovascularization Secondary to Pathologic Myopia
NCT06176352Phase 3Completed
- Sponsor
- Roche
- Start
- Mar 2024
- Primary completion
- May 2026
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 11
01
Overview
A Phase 3 trial of faricimab in choroidal neovascularization (CNV), sponsored by Roche. Started Mar 2024; status: completed.
02
Drugs
faricimab
03
Conditions
choroidal neovascularization (CNV)
Beyond the preview
Go deeper on NCT06176352.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06176352.